Testimony before the FDA’s Pulmonary and Allergy Drugs Advisory Committee on umeclidinium/vilanterol (proposed trade name Anoro Ellipta) for the long-term treatment of patients with chronic obstructive pulmonary disease (COPD)

View as PDF.

Public Citizen opposes the approval of the combination therapy umeclidinium/vilanterol (proposed trade name Anoro Ellipta) for the treatment of COPD because the drug led to a higher rate of abnormal heart rhythms and non-fatal heart attacks in the pre-approval clinical trials.